At present, it has only been reported that HRD1 is the E3 ligase of CPT2 in triple-negative breast cancer, and whether there are other E3 ligases or deubiquitinating enzymes in CPT2 is still unclear. This evidence concerns the gene CPT2 and triple-negative breast carcinoma.